Literature DB >> 18209040

Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers.

Maria Cecilia Huaman1, Laura B Martin, Elissa Malkin, David L Narum, Louis H Miller, Siddhartha Mahanty, Carole A Long.   

Abstract

A number of blood-stage malaria Ags are under development as vaccine candidates, but knowledge of the cellular responses to these vaccines in humans is limited. We evaluated the nature and specificity of cellular responses in healthy American volunteers vaccinated with a portion of the major merozoite surface protein-1 (MSP1) of Plasmodium falciparum, MSP1(42), formulated on Alhydrogel. Volunteers were vaccinated three times with 80 microg of either MSP1(42)-FVO/Alhydrogel or MSP1(42)-3D7/Alhydrogel. Cells collected 2 wk after the third vaccination produced Th1 cytokines, including IFN-gamma and IL-2 following Ag stimulation, and greater levels of the Th2 cytokines IL-5 and IL-13; the anti-inflammatory cytokine IL-10 and the molecule CD25 (IL-2Ralpha) were also detected. The volunteers were evaluated for the MSP1(42)-FVO or MSP1(42)-3D7 specificity of their T cell responses. Comparison of their responses to homologous and heterologous Ags showed ex vivo IFN-gamma and IL-5 levels that were significantly higher to homologous rather than to heterologous Ags. The epitopes involved in this stimulation were shown to be present in the dimorphic MSP1(33) portion of the larger MSP1(42)-3D7 polypeptide, and indirect experiment suggests the same for the MSP1(42)-FVO polypeptide. This contrasts with B cell responses, which were primarily directed to the conserved MSP1(19) portion. Furthermore, we explored the maturation of memory T cells and found that 46% of vaccinees showed specific memory T cells defined as CD4(+)CD45RO(+)CD40L(+) after long-term in vitro culture. The identification of human-specific CD4(+) memory T cells provides the foundation for future studies of these cells both after vaccination and in field studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209040     DOI: 10.4049/jimmunol.180.3.1451

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.

Authors:  James R Alaro; Michele M Lynch; James M Burns
Journal:  Vaccine       Date:  2010-08-13       Impact factor: 3.641

2.  Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.

Authors:  Michele D Spring; Kiprotich Chelimo; Daniel J Tisch; Peter Odada Sumba; Rosemary Rochford; Carole A Long; James W Kazura; Ann M Moormann
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

Review 3.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

4.  Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.

Authors:  Ann M Moormann; Peter Odada Sumba; Kiprotich Chelimo; Hua Fang; Daniel J Tisch; Arlene E Dent; Chandy C John; Carole A Long; John Vulule; James W Kazura
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

5.  Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses.

Authors:  Ann M Moormann; Kevin N Heller; Kiprotich Chelimo; Paula Embury; Robert Ploutz-Snyder; Juliana A Otieno; Margaret Oduor; Christian Münz; Rosemary Rochford
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

6.  A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Authors:  James R Alaro; Andrea Partridge; Kazutoyo Miura; Ababacar Diouf; Ana M Lopez; Evelina Angov; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

7.  Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8.

Authors:  James R Alaro; Evelina Angov; Ana M Lopez; Hong Zhou; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2012-05-14       Impact factor: 3.441

8.  Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.

Authors:  Simon J Draper; Anna L Goodman; Sumi Biswas; Emily K Forbes; Anne C Moore; Sarah C Gilbert; Adrian V S Hill
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

Review 9.  How might infant and paediatric immune responses influence malaria vaccine efficacy?

Authors:  A M Moormann
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

10.  Immunization with an immunodominant self-peptide derived from glucose-6-phosphate isomerase induces arthritis in DBA/1 mice.

Authors:  Lisa Bruns; Oliver Frey; Lars Morawietz; Christiane Landgraf; Rudolf Volkmer; Thomas Kamradt
Journal:  Arthritis Res Ther       Date:  2009-07-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.